Original Papers - Oncology Open access

Introducing “HEDGE”: sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer

Authors

Published
9 September 2026
Section
Original Papers - Oncology

Abstract

Introduction: BCG-unresponsive non-muscleinvasive bladder cancer (NMIBC) remains a major clinical challenge, with radical cystectomy recommended yet frequently declined or deferred. We introduce a regimen that combines hyperthermic intravesical chemotherapy (HIVEC) with gemcitabine immediately followed by intravesical docetaxel, which we named as “HEDGE” (HE = HIVEC, D = Docetaxel, GE = Gemcitabine). The rationale integrates: (i) the Guidelines of the European Association of Urology (GEAU) construct of BCG-unresponsive disease as unlikely to benefit from further BCG; (ii) clinical experience supporting HIVEC-based chemotherapy; (iii) the growing evidence base for sequential gemcitabine/docetaxel; and (iv) experimental confirmation that gemcitabine remains stable at elevated temperatures, supporting its use within HIVEC circuits.

Materials and methods: BCG-unresponsive patients, according to the definition of the GEAU on NMIBC, were prospectively selected to receive “HEDGE”. “HEDGE” consists of sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) and intravesical docetaxel. It includes induction and maintenance scheme. Primary endpoints are recurrence and progression at 3, 6, 9, and 12 months. Secondary endpoints are feasibility and safety through documentation of adverse events (AE) based on The Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA) (National Cancer Institute/NCI, 2025). We applied this treatment to 7 patients (5 men, 2 women).

Results: The included patients showed neither recurrence nor progression at 3 and 6 months. Finally, we documented Grade 2 AE in only 3 patients.

Conclusions: “HEDGE” looks feasible, safe, and showed no three- and six month recurrences in our first 7 BCG unresponsive NMIBC patients, supporting further clinical implementation and evaluation. This could be a therapeutic option for these patients.

Ethics Approval

This work was conducted in accordance with the principles of the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declarationof- helsinki/) and was reviewed and approved by the Institutional Review Board (IRB) of the University Hospital of Larissa. Informed consent was obtained from all individual participants included in the study.

Data Availability Statement

All the authors confirm that all data underlying the findings are fully available without restriction and all data are included within the manuscript.

References

  1. 1. Brierley JD, Giuliani M, O’ Sullivan B, et al. Union International Contre le Cancer/UICC, TNM Classification of Malignant Tumours, 9th Edition, ISBN: 978-1-394-21687-1, Wiley; 2025.
  2. 2. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. EAU Guidelines Office, Arnhem, The Netherlands.
  3. 3. Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016; 34:1935-44. DOI: https://doi.org/10.1200/JCO.2015.64.4070
  4. 4. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and CIS bladder tumors. J Urol. 2000; 163:1124-1129. DOI: https://doi.org/10.1016/S0022-5347(05)67707-5
  5. 5. Jing L, Wenjian C, Meimei Z, et al. Novel device with gemcitabine for hyperthermic intravesical chemotherapy: development and investigation. Int J Hyperthermia. 2023;40:2129103. DOI: https://doi.org/10.1080/02656736.2022.2129103
  6. 6. Lammers RJ, Witjes JA, Inman BA, et al. Intravesical chemotherapy with hyperthermia in NMIBC: a systematic review. Eur Urol. 2011; 60:81-93. DOI: https://doi.org/10.1016/j.eururo.2011.04.023
  7. 7. Kastner L, Rieger C, Pfister D, et al. HIVEC as an alternative option in non-muscle invasive bladder cancer: Experiences from a high volume center. Urol Oncol. 2024;42:245.e19-245.e26. DOI: https://doi.org/10.1016/j.urolonc.2024.01.300
  8. 8. McElree IM, Steinberg RL, Martin AC, et al. Sequential intravesical gemcitabine and docetaxel for BCG naïve high risk NMIBC. J Urol. 2022; 208:589-599. DOI: https://doi.org/10.1097/JU.0000000000002740
  9. 9. McElree IM, Steinberg RL, Mott SL, et al. Gemcitabine/docetaxel versus BCG for high risk NMIBC. JAMA Netw Open. 2023; 6:e230849. DOI: https://doi.org/10.1001/jamanetworkopen.2023.0849
  10. 10. Tan WS, McElree IM, Davaro F, et al. Sequential intravesical gemcitabine and docetaxel as an alternative to BCG in intermediate risk NMIBC. Eur Urol Oncol. 2023; 6:531-534. DOI: https://doi.org/10.1016/j.euo.2023.06.011
  11. 11. National Cancer Institute, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Vesrion 6.0, 2025, NCI CTCAE and AE Reporting Site.
  12. 12. Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur. Urol. 2019; 75:63-71. DOI: https://doi.org/10.1016/j.eururo.2018.09.005
  13. 13. Stauffer PR, Van Rhoon GC. Overview of bladder heating technology: Matching capabilities with clinical requirements. Int. J. Hyperth. 2016; 32:407-416. DOI: https://doi.org/10.3109/02656736.2016.1141239
  14. 14. Van Hattum JW, Scutigliani EM, Helderman RFCPA, et al. A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer. Sci. Rep. 2022;12:7017. DOI: https://doi.org/10.1038/s41598-022-11016-y
  15. 15. Bahouth Z, Halachmi S, Moskovitz B, Nativ O. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. Expert Rev. Anticancer Ther. 2016;16:189-198. DOI: https://doi.org/10.1586/14737140.2016.1126515
  16. 16. Plata A, Guerrero-Ramos F, Garcia C, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J. Clin. Med. 2021; 10:5105. DOI: https://doi.org/10.3390/jcm10215105
  17. 17. Colombo R, Da Pozzo LF, Lev A, et al. Local Microwave Hyperthermia and Intravesical Chemotherapy as Bladder Sparing Treatment for Select Multifocal and Unresectable Superficial Bladder Tumors. J Urol. 1998; 159:783-787. DOI: https://doi.org/10.1016/S0022-5347(01)63728-5
  18. 18. Thomsen JA, Nielsen Dominiak H, Lindgren MS, Jensen JB. Adverse events of hyperthermic intravesical chemotherapy for nonmuscle invasive bladder cancer patients. Scand. J Urol. 2021;55:281-286. DOI: https://doi.org/10.1080/21681805.2021.1938664
  19. 19. Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br. J Clin Pharmacol. 2001; 52:273-278. DOI: https://doi.org/10.1046/j.0306-5251.2001.01449.x
  20. 20. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 2003; 21:4270-4276. DOI: https://doi.org/10.1200/JCO.2003.01.089
  21. 21. González-Padilla DA, González-Díaz A, Guerrero-Ramos F, et al. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. Urol. Oncol. 2021; 39:76.e9-76.e14. DOI: https://doi.org/10.1016/j.urolonc.2020.07.003
  22. 22. Lidagoster S, Ben-David R, De Leon B, Sfakianos JP. BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer. Curr Oncol. 2024; 31:1063-1078. DOI: https://doi.org/10.3390/curroncol31020079
  23. 23. Roumiguié M, Black PC. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG unresponsive Non-muscle-invasive bladder cancer: Pro. Eur. Urol. Focus 2022; 8:1117-1120. DOI: https://doi.org/10.1016/j.euf.2021.07.018
  24. 24. Yim K, Melnick K, Mott SL, et al. Sequential intravesical gemcitabine/ docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol. Oncol. Semin. Orig. Investig. 2023; 41:458.e1-458.e7. DOI: https://doi.org/10.1016/j.urolonc.2023.06.018
  25. 25. A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive Non-Muscle Invasive Bladder Cancer (The BRIDGE Trial)—NCI. Available online: https://www.cancer.gov/research/participate/clinicaltrials-search/v?id=NCI-2022-04864&r=1 (accessed on 2 December 2023).

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.